课题基金 / 基金详情

项目摘要

项目成果

KATHERINE S. POLLARD的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要/摘要 这个P01项目的目标是识别生物标志物,使我们能够预测滞后的可能持续时间 在#年停止抗逆转录病毒治疗(ART)后艾滋病毒反弹之前的阶段或“缓解”期 感染艾滋病毒的人。在我们的研究中,大量的病毒学和免疫学参数将被 在接受分析治疗的约125名特征良好的艾滋病毒感染者队列中进行测量 中断(ATI),以确定这些测量是否允许我们可靠地预测病毒的动力学 艺术后反弹停止。包括下一代测序在内的大量高维数据 数据(转录本和microRNA图谱)和CyTOF数据将在我们提议的实验中生成。 生物信息学和生物统计核心将在汇编、管理、分析和 传播在与本P01申请有关的所有三个项目中产生的数据。为了最大限度地利用我们的 识别有意义的签名的机会预测病毒反弹之前的时间,我们将实施几个 统计方法和集合学习方法(例如,梯度增强、随机森林)以开发 理论,我们将依靠已建立的分类器性能评估程序(例如,交叉验证, 递归特征消除和特征重要性测量)来严格确定预测潜力 正在考虑的生物标记物。 在我们的生物信息学和生物统计学核心项目的目标1中,我们将评估假设的个人能力 在项目2中研究了血细胞相关生物标志物,以预测ATI后病毒反弹的时间。 测量包括在CD4+T细胞中复制能力强的前病毒基因组的频率 宿主细胞转录组的特征。在目标2中,我们将评估单个假定细胞的能力- 在项目3中研究了血浆和脑脊液来源的游离生物标志物,以预测ATI后病毒反弹的时间。 测量包括循环microRNA图谱、细胞外小泡表型和多种细胞因子。 和抗体特性。最后,在目标3中,我们将对所有3个生物标志物进行联合分析 项目(包括项目1中生成的细胞免疫表型数据)以评估它们的相对性能 并确定预测者之间的潜在协同效应。集成学习方法是发现 预测特征的复杂组合。它们还提供了评估预测性数据的框架 候选生物标记物单独或与其他生物标记物结合的重要性。 生物信息学和生物统计核心将在实现我们的P01目标和 推进艾滋病毒治疗议程,将丰富多样的高维数据转化为稳健 抗逆转录病毒治疗中断后艾滋病毒反弹的预测指标。
英文摘要
PROJECT SUMMARY/ABSTRACT The goal of this P01 project is to identify biomarkers that will enable us to predict the likely duration of the lag phase or “remission” period prior to HIV rebound following discontinuation of antiretroviral therapy (ART) in HIV-infected individuals. In our study, a large number of virologic and immunologic parameters will be measured in a cohort of ~125 well-characterized HIV-infected individuals undergoing analytical treatment interruption (ATI), to determine if any of these measurements allow us to reliably predict the kinetics of viral rebound post-ART cessation. A large amount of high-dimensional data including next-generation sequencing data (transcriptomes and microRNA profiles) and CyTOF data will be generated in our proposed experiments. The Bioinformatics and Biostatistics Core will play a leading role in compiling, curating, analyzing and disseminating data generated in all three projects associated with this P01 application. To maximize our chances of identifying meaningful signatures predicting time until viral rebound, we will implement several statistical approaches and ensemble learning methods (e.g., gradient boosting, random forests) to develop theories, and we will rely on established classifier performance evaluation procedures (e.g. cross validation, recursive feature elimination, and feature importance measures) to rigorously determine the predictive potential of biomarkers under consideration. In Aim 1 of our Bioinformatics and Biostatistics Core project, we will evaluate the capacity of individual putative blood cell-associated biomarkers studied in Project 2 to predict time until viral rebound following ATI. Measurements include the frequency of replication-competent proviral genomes in CD4+ T cells and global characterization of the host cell transcriptome. In Aim 2, we will evaluate the capacity of individual putative cell- free plasma- and CSF-derived biomarkers studied in Project 3 to predict time until viral rebound following ATI. Measurements include circulating microRNA profile, extracellular vesicle phenotype, and multiplex cytokine and antibody characterization. Lastly, in Aim 3, we will perform a combined analysis of biomarkers across all 3 projects (including CyTOF immunophenotypic data generated in Project 1) to assess their relative performance and to identify potential synergies between predictors. Ensemble learning methods are ideal for discovering complex combinations of predictive features. They also provide a framework for evaluating the predictive importance of candidate biomarkers both individually and in combination with other biomarkers. The Bioinformatics and Biostatistics Core will play a central role in achieving our P01 objectives and in advancing the HIV cure agenda, transforming copious and diverse, high-dimensional data into robust predictors of HIV rebound following ART interruption.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Discovering human divergent activity-regulated elements using comparative, computational, and functional approaches
Linking microbiome genetic variants with cardiovascular phenotypes in 50,000 individuals
  • 批准号:
    10516693
  • 项目类别:
  • 资助金额:
    $70.73万
  • 财政年份:
    2022
  • 负责人:
    KATHERINE S. POLLARD
  • 依托单位:
Linking microbiome genetic variants with cardiovascular phenotypes in 50,000 individuals
  • 批准号:
    10672312
  • 项目类别:
  • 资助金额:
    $68.5万
  • 财政年份:
    2022
  • 负责人:
    KATHERINE S. POLLARD
  • 依托单位:
Core B: Integrative Data-Science Core
  • 批准号:
    10670335
  • 项目类别:
  • 资助金额:
    $63.77万
  • 财政年份:
    2021
  • 负责人:
    KATHERINE S. POLLARD
  • 依托单位:
海外基金